Mechanism of action of dopaminergic agents in Parkinson's disease

Neurology
W C Koller, M G Rueda

Abstract

As the substantia nigra degenerates in Parkinson's disease (PD), the nigrostriatal pathway is disrupted, reducing striatal dopamine and producing PD symptoms. Although dopamine does not readily cross the blood-brain barrier, its precursor, levodopa, does. Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and catechol-O-methyltransferase (COMT). Because gastric AADC and COMT degrade levodopa, the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use. Although the exact site of decarboxylation of exogenous levodopa to dopamine in the brain is unknown, most striatal AADC is located in nigrostriatal dopaminergic nerve terminals. Newly synthesized dopamine is stored in the terminals and then released, stimulating postsynaptic dopamine receptors and mediating the antiparkinsonian action of levodopa. Dopamine agonists act directly on postsynaptic dopamine receptors, thus obviating the need for metabolic conversion, storage, and release. How the actions of dopaminergic drugs produce side effects and how these side effects should be managed are discussed.

Citations

Jul 18, 2001·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·M DahlinE Björk
Aug 2, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Caterina BreitensteinStefan Knecht
Apr 14, 2010·Expert Opinion on Drug Metabolism & Toxicology·Nelida FernandezMatilde Sierra
Mar 6, 2012·Neuroscience Letters·Pamela SabioniJosé C F Galduróz
Nov 3, 2010·Journal of Pharmaceutical and Biomedical Analysis·F BugamelliM A Raggi
Jun 13, 2009·Behavioural Brain Research·Amy M KnabJ Timothy Lightfoot
Oct 27, 2007·Seminars in Cell & Developmental Biology·Vanessa J HallPatrik Brundin
Apr 23, 2015·Human Psychopharmacology·Leanne ShellshearDavid A Copland
Dec 5, 2008·Neurologic Clinics·Kelvin L Chou
Mar 18, 2000·Archives of Physical Medicine and Rehabilitation·J A Sliwa
Aug 20, 2016·Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy·Maha F Abdel-GhanyMenatallah M Youssef
Jul 25, 2008·Biological Psychiatry·Emma AshwinSimon Baron-Cohen
May 22, 2016·Diabetes·Yonah B EstersonMeredith Hawkins
Feb 9, 2000·Psychosomatics·L Marsh
Oct 4, 2005·Journal of Pharmaceutical Sciences·Ayman AllahhamDavid Mainwaring
Dec 12, 2001·Endocrine Reviews·N Ben-Jonathan, R Hnasko
Nov 6, 2018·The Pharmacogenomics Journal·Alon BotzerRon Unger
Jan 23, 2020·AACE Clinical Case Reports·Camilla Maria Guimarães AugustoMarcos Oliveira Pires de Almeida
Jan 11, 2019·Molecular Psychiatry·Zachary J FarinoZachary Freyberg
Nov 22, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Felix MüllerStefan Borgwardt
Nov 23, 2020·The European Journal of Neuroscience·Gadi GoelmanRobert Jech
Jan 5, 2021·Frontiers in Behavioral Neuroscience·Christian ChristensenKarl Ægir Karlsson
Jul 17, 2021·Neurochemistry International·Sidrah Tariq KhanAhmed Al-Harrasi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.